Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000487873 | SCV000231386 | uncertain significance | not provided | 2015-05-08 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV000245458 | SCV000309945 | likely benign | not specified | criteria provided, single submitter | clinical testing | ||
Ambry Genetics | RCV000247407 | SCV000318924 | benign | Cardiovascular phenotype | 2019-12-02 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Ce |
RCV000487873 | SCV000575627 | uncertain significance | not provided | 2016-11-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001085409 | SCV000625964 | benign | Duchenne muscular dystrophy | 2024-01-31 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV001085409 | SCV001652767 | likely benign | Duchenne muscular dystrophy | 2021-05-18 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001826915 | SCV002087694 | likely benign | Becker muscular dystrophy; Duchenne muscular dystrophy; Cardiomyopathy; Dystrophin deficiency | 2017-08-09 | no assertion criteria provided | clinical testing |